Learn About Beta-Mannosidosis

What is the definition of Beta-Mannosidosis?

Beta-mannosidosis is a rare inherited disorder affecting the way certain sugar molecules are processed in the body.

What are the causes of Beta-Mannosidosis?

Variants (also known as mutations) in the MANBA gene cause beta-mannosidosis. The MANBA gene provides instructions for making the enzyme beta-mannosidase. This enzyme works in the lysosomes, which are compartments that digest and recycle materials in the cell. Within lysosomes, the enzyme helps break down complexes of sugar molecules (oligosaccharides) attached to proteins (glycoproteins). Beta-mannosidase is involved in the last step of this process, helping to break down complexes of two sugar molecules (disaccharides) containing a sugar molecule called mannose.

How prevalent is Beta-Mannosidosis?

Beta-mannosidosis is believed to be a very rare disorder. It is difficult to determine the specific incidence of beta-mannosidosis, because people with mild or non-specific symptoms may never be diagnosed.

Is Beta-Mannosidosis an inherited disorder?

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have variants. The parents of an individual with an autosomal recessive condition each carry one copy of the altered gene, but they typically do not show signs and symptoms of the condition.

Who are the top Beta-Mannosidosis Local Doctors?
Julie A. Biller
Advanced in Beta-Mannosidosis
Pulmonary Medicine | Pediatric Pulmonology
Advanced in Beta-Mannosidosis
Pulmonary Medicine | Pediatric Pulmonology

The Medical College Of Wisconsin Inc

8701 Watertown Plank Rd, Room 4041 Mfrc, 
Milwaukee, WI 
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Julie Biller is a Pulmonary Medicine specialist and a Pediatric Pulmonologist in Milwaukee, Wisconsin. Dr. Biller is rated as an Advanced provider by MediFind in the treatment of Beta-Mannosidosis. Her top areas of expertise are Cystic Fibrosis, Secondary Immunodeficiency (SID), Newborn Jaundice, and Lung Metastases. Dr. Biller is currently accepting new patients.

Distinguished in Beta-Mannosidosis
Neurology | Pediatric Neurology
Distinguished in Beta-Mannosidosis
Neurology | Pediatric Neurology
200 1st St Sw, 
Rochester, MN 
Languages Spoken:
English
Accepting New Patients

Deborah Renaud is a Neurologist and a Pediatric Neurologist in Rochester, Minnesota. Dr. Renaud is rated as a Distinguished provider by MediFind in the treatment of Beta-Mannosidosis. Her top areas of expertise are Beta-Mannosidosis, Leukodystrophy, CACH Syndrome, and Alpha Mannosidosis. Dr. Renaud is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Distinguished in Beta-Mannosidosis
Distinguished in Beta-Mannosidosis

Juan A Fernandez MD PA

5040 Nw 7th St, Suite 370, 
Miami, FL 
Languages Spoken:
English, Spanish
Accepting New Patients

Juan Fernandez is a Nephrologist in Miami, Florida. Dr. Fernandez is rated as a Distinguished provider by MediFind in the treatment of Beta-Mannosidosis. His top areas of expertise are Schindler Disease, Fucosidosis, Beta-Mannosidosis, Aspartylglucosaminuria, and Gastrostomy. Dr. Fernandez is currently accepting new patients.

What are the latest Beta-Mannosidosis Clinical Trials?
A Phase II Study of Reduced Intensity Conditioning in Pediatric Patients and Young Adults ≤55 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation

Summary: The objective of this study is to evaluate the efficacy of using a reduced-intensity condition (RIC) regimen with umbilical cord blood transplant (UCBT), double cord UCBT, matched unrelated donor (MUD) bone marrow transplant (BMT) or peripheral blood stem cell transplant (PBSCT) in patients with non-malignant disorders that are amenable to treatment with hematopoietic stem cell transplant (HSCT). ...

Match to trials
Find the right clinical trials for you in under a minute
Get started
MT2013-31: Allogeneic Hematopoietic Cell Transplantation for Inherited Metabolic Disorders and Severe Osteopetrosis Following Conditioning With Busulfan (Therapeutic Drug Monitoring), Fludarabine +/- ATG

Summary: This single-institution, phase II study is designed to test the ability to achieve donor hematopoietic engraftment while maintaining low rates of transplant-related mortality (TRM) using busulfan- and fludarabine-based conditioning regimens with busulfan therapeutic drug monitoring (TDM) for patients with various inherited metabolic disorders (IMD) and severe osteopetrosis (OP).

Who are the sources who wrote this article ?

Published Date: February 01, 2023
Published By: National Institutes of Health